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ABSTRACT 
Background 
Factors such as age, gender and genetic polymorphisms may explain individual difference in 
pain phenotype.  Genetic associations to pain sensitivity have previously been investigated in 
osteoarthritis patients with focus on the P2X7, TRPV1 and TACR1 genes. However, other 
genes may play a role as well. Osteoarthritis is a common joint disease and many patients 
suffering from this disease are thought to have increased sensitivity to noxious stimuli 
resulting from sensitization in the nociceptive system. The aim of the study was to investigate 
if genetic variants of mu, kappa, and delta opioid receptor genes (OPRM1, OPRK1, and 
OPRD1), and the catechol-O-methyltransferase gene (COMT) influenced the pain phenotype 
in patients with osteoarthritis. 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Methods  
The frequencies of seventeen polymorphisms were examined. Pain sensitivity was assessed 
pre-operatively by: 1) hip rotation; 2) contact heat stimulation; 3) conditioned pain 
modulation effect and 4) pressure stimulation at the tibia in both the affected and the 
unaffected leg.  
Results 
Ninety-two patients (mean age 66 years) with unilateral hip osteoarthritis were included in 
the study. Carriage of the OPRM1 rs589046T allele was found to be associated with 
increased pain rating during hip rotation (P=0.04) and increased conditioned pain modulation 
(P=0.049). Carriage of the OPRD1 rs2234918C allele was found to be associated with 
increased pain detection threshold to contact heat stimulation (P=0.001). No other 
associations were found (all P > 0.05). 
Conclusion 
Results from the present study suggest that, in patients with hip osteoarthritis, genetic 
variants in OPRM1 and OPRD1 may contribute to the pain phenotype.  
 
INTRODUCTION 
Osteoarthritis (OA) is the most common joint disease worldwide 
1
. Many patients with OA 
are thought to have increased sensitivity to noxious stimuli resulting from sensitization in the 
nociceptive system 
2
. Age, gender, height and genetic polymorphisms are some factors that 
may explain individual difference in pain sensitivity 
3–6
.  
 
Human genetic association studies have provided insight into the inter-individual variability 
in pain sensitivity 
7–10
. For example,  P2X7, TRPV1 and TACR1 genes have been studied in 
OA patients 
11–13
. However, other genes may also play a role, for example, rs4680A/G and 
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rs6269A/G in the COMT gene 
14,15
. Additionally, single nucleotide polymorphisms (SNPs) in 
the mu, kappa and delta opioid receptor genes (OPRM1, OPRK1, OPRD1) have shown to 
alter pain sensitivity through variations in receptor function 
8,16,17
. However, findings are still 
inconclusive.  
 
Inconclusive results may be explained by different methodologies used 
7
. Moreover, socio-
psychological confounders may blur the findings in the clinical setting.  Such confounders 
can be avoided in studies using experimentally induced pain in healthy volunteers 
18
. On the 
other hand, it is not possible to reproduce the full complexity of clinical pain and external 
validity may be limited 
19
. Thus, using a combination where experimentally noxious stimuli 
are induced in patients suffering from pain might be advantageous, when trying to elucidate 
the genetic factors influencing pain sensitivity. In patients with OA the inflammation process 
causes peripheral sensitization (the primary afferent neurons in the joint are sensitized) and 
central sensitization (neurons in the central nervous system receiving the input from the 
inflamed joint are hyperexcitable and undergo neuroplastic changes) 
20
. The influence of 
inflammation on pain perception can therefore be investigated by applying experimentally 
induced pain in these patients. Additionally, it is possible to induce an acute clinical pain by 
for example rotating the hip.  
 
We hypothesized that application of experimental pain models in a clinical setting would 
elucidate if, carriers of the minor alleles of COMT or OPRM1 or OPRK1 or OPRD1 have 
altered pain sensitivity as compared to non-carriers. Thus, the aims were to compare the 
following variables in the two groups (carriers versus non-carriers): 1) clinical pain rating 
during hip rotation; 2) pain reported during contact heat stimulation of the forearm; 3) 
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conditioned pain modulating (CPM) effect; 4) pain pressure threshold at tibia distal to the 
affected and unaffected hip for each polymorphism separately.  
 
METHODS 
The trial was conducted by the Department of Pain Medicine, Clinic for Anesthesiology, 
University Hospital, Georg-August-university of Göttingen, Germany, and the Department of 
Anesthesiology and Intensive Care, Annastift, Hannover, between April and August 2013. 
The study was approved by the Ethical committees of the University Hospital of Göttingen 
(No 5/4/12) and the Medical School Hannover (No. 1483-2012). Written informed consent 
was obtained from the patients before the study procedures. The study was carried out 
according to the recommendations of the Helsinki declaration (2013). Patient recruitment and 
pain assessments were performed at the Annastift, Hannover. The results regarding the 
primary endpoints from the study has previously been published (Prediction of postoperative 
opioid analgesia using machine learning and encephalography) 
21
. This manuscript concerns 
the secondary endpoint of the protocol.  
 
Patients 
The included patients suffered from hip OA and were scheduled to undergo total hip 
replacement surgery. A total of 175 patients were screened for participation. Inclusion criteria 
were: 1) older than 18 years old, 2) capacity to give the consent on his/her own, and 3) had 
sufficient knowledge of the German language to understand the study information and the 
required questionnaires. Exclusion criteria were: 1) severe neurological disease; 2) severe 
psychiatric disease like major depression or schizophrenia or active drug abuse; 3) a high 
dose of opioid therapy (> 30 mg oral morphine equivalent dose per day); and 4) participation 
in other studies conducted at the same time.  
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Procedure 
Patients were usually admitted to hospital on the day before surgery. Thus, patients were 
recruited in the morning of the day prior to surgery. After consent was obtained the pain 
history was registered, followed by completion of questionnaires (in waiting time between 
the hospital procedures). The functional testing and pain assessments were conducted in the 
afternoon of the pre-operative day (figure 1).  
 
Patients refrained from smoking as well as drinking coffee or other caffeine-containing 
beverages 1-2 hours prior to the assessment of pain sensitivity. Additionally, the patients 
were familiarized with the various procedures and given standardized test instructions. To 
avoid investigator emerging biases, all psychophysiological measurements were done by the 
same researcher (MR).  
Opioid consumption (substance and dose) was registered for each patient.  
 
Passive hip rotation 
The  perceived intensity of evoked pain with passive rotation of the hip scheduled for 
replacement was assesed on an 11-point numerical rating scale (NRS), where 0 was “no pain” 
and 10 “worst imaginable pain”. First, the hip was brought into a 90° flexed position, with the 
knee flexed at 90° at the same time, and then slowly rotated interiorly until the patient 
reported the first onset of pain, the pain detection threshold (PDT). Then, the passive rotation 
was continued until the pain threshold was reached and this position was maintained for 30 
seconds. Afterwards the patients were asked to rate the evoked pain on a NRS and this value 
was used for further analysis. In patients who could not tolerate this choreography (i.e. with 
severe pain already with hip flexion), hip flexion was used as the stimulus.  
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Quantitative sensory testing (QST) 
Contact heat stimulation 
Contact heat stimulation was determined by a computer driven heat pain device (TSA-II 
NeuroSensory Analyzer, Medoc Ltd, Ramat Yishai, Israel). A thermode was applied to the 
volar surface of the dominant forearm at 10 cm from the elbow. The temperature increased 
gradually from 32°C to a maximum of 52°C at a rate of 1°C/s until the patient reached PDT. 
The stimulation was stopped, when the patient clicked a button. Four consecutive temperature 
measurements were performed and the average of the last three PDTs was computed and 
retained for further analysis.  
 
Conditioned pain modulation effect (CMP) 
To assess descending inhibitory pain modulation a CPM paradigm was carried out. CPM was 
measured as the change in pain sensitivity to a test stimulus before (pre-CPM) and during 
(peri-CPM) a conditioned pain stimulus 
22
. The conditioned pain stimulus was performed the 
following way: The patient’s hand was immersed in cooled water (around 8 °C) for 2 minutes 
or less if the pain was intolerable for the patient. Contact heat PDTs were repeated at 60, 90 
and 120 seconds after immersion of the hand in cold water. CPM effect was calculated for the 
PDT to contact heat stimulation as the percentage change from baseline [e.g.(T120min-
baseline)/baseline*100%]. The time point with the highest CPM effect was used for further 
analysis.  
 
Pressure pain detection threshold  
Pressure pain threshold was assessed at the tibial bone, 15 cm below the patella. A handheld 
electronic pressure algometer (Somedic AB, Stockholm, Sweden) was used. The pressure rate 
was gradually increased with 30 kPa/sec until the patients reported PDT. Maximum pressure 
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intensity applied was 1000 kPa. Altogether four measurements were recorded within close 
proximity. The mean pressure intensity (kPa) at PDT was calculated as the mean of the last 
three measures and was used for further analysis.  
 
DNA extraction and genotyping 
Genomic DNA was extracted from an aliquot of venous blood with the QIAsymphony DSP 
DNA Midi kit (Qiagen, Copenhagen, Denmark) using the QIAsymphony
TM
 SP instrument 
(Qiagen, Copenhagen, Denmark). Selected SNPs in COMT (rs4680A/G), OPRM1 
(rs1799971A/G, rs589046C/T, rs563649C/T, rs9479757G/A, rs533586C/T), OPRK1 
(rs16918875C/T, rs7016778T/A, rs10504151T/C, rs7836120A/G, rs6473799T/C, 
rs1365098G/T, rs7824175G/C, rs963549G/A), and OPRD1 (rs533123G/A, rs2236857T/C, 
rs2234918C/T) were genotyped using predesigned TaqMan SNP genotyping assays on a 
StepOne Plus real-time instrument (Applied Biosystems, Foster City, California, USA).  
Genotyping was conducted in accordance with the manufacturer’s protocol. The choice of 
candidate SNPs was based on location along the gene (i.e. SNPs in regions most likely to 
have an impact on gene function were selected), and the existence of published data for the 
specific SNPs. Thus, within each selected gene, SNPs were selected in attempt to cover the 
allelic diversity.  
 
Statistical analysis and considerations 
The Chi-square goodness-of-fit test (Haploview version 4.2, Broad Institute, Cambridge, 
USA) was used to determine if all genotype frequencies were in Hardy-Weinberg 
equilibrium. The demographic characteristics for all patients are presented as medians with 
25
th
 to 75
th
 percentile. The demographic characteristics for carriers and non-carriers of the 
minor alleles were both visually inspected as histograms with corresponding normal curve 
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and analyzed by Shapiro-Wilk test to test for normality (P<0.05 indicate non-normally 
distributed data). Age, weight, and body mass index (BMI) were non-normally distributed 
and Man-Whitney U-test was used as non-parametric test. Height and duration of hip pain 
were normally distributed, and analyzed using parametric t-tests. Categorical variable such as 
gender were analyzed by Fisher’s exact test. All tested genetic variants were bi-allelic SNPs, 
and it was unknown whether the variant allele could be a risk-enhancing allele (increases the 
likelihood of a poorer outcome) or a protective allele (increase the likelihood of improving 
the outcome). Thus, genotype distributions were calculated for subjects homozygous (AA) 
and heterozygous (AB) for the A allele (minor allele), and for subjects homozygous (BB) for 
the B allele (major allele). The genetic association analysis included two groups: Carriers of 
the minor allele (AA+AB) and non-carriers of the minor allele (BB). Correction for 
confounders, such as age, BMI and duration of hip pain, were not conducted as no difference 
was seen between carriers and non-carriers of the minor alleles in any genes. However, 
parametric multiple regressions adjusted for “gender” and “opioid treatment versus no opioid 
treatment” was used in the evaluation of the association of genetic variations in OPRM1, 
OPRD1, OPRK1 and COMT with the investigated assessments of pain sensitivity. No 
adjustment for multiple testing was performed as the genetic variations are known to be 
associated to the pain sensitivity 
23
. All statistical analyses were conducted in STATA 12.0 
(StataCorp, Texas, US), and the results are presented as mean with corresponding 95% 
confidence interval. A P-value smaller than 0.05 was considered significant, and effect sizes 
are presented as the differences between the means of the two groups.  
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RESULTS 
For this study, 112 patients signed the informed consent. Data from twenty of these patients 
were not included in the final analysis for different reasons as described in figure 2.  Thus, 
data from 92 patients (50 females and 42 males) were included in the analysis. The median 
age was 66 years, with a range from 58 to 74 years. The with a body mass index of 27 kg/m
2
 
(25-31 kg/m
2
). Median height and weight were 171 cm (164-176 cm; n = 90) and 83 kg (68-
90 kg; n = 91), respectively.  
 
All investigated SNPs were in Hardy-Weinberg equilibrium. The genotype distribution and 
corresponding demographic characteristics are presented in Table 1. The allele frequencies 
for the SNPs in OPRM1, OPRK1, OPRD1, and COMT were similar to the allele frequencies 
of the HapMap-CEU project  
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_viewTable.cgi?pop=1409). With regard to 
OPRM1 rs533586 SNP, the allele frequency was comparable to allele frequency of the 
CEU_GENO_PANEL project 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_viewTable.cgi?pop=4720). Furthermore, in 
this cohort we found that the OPRM1 rs9479757G allele was more frequent than the 
rs9479757A allele, which was in agreement with results published by Beer et al. (2013) 
24
. 
Nonetheless, we have previously found the reverse trend in another cohorte in rs9479757 
allele frequency, showing that rs9479757A allele was the most frequent 
25
.  
Pain sensitivity and gender 
Results for pain sensitivity in males and females are shown in Table 2. There was a 
significant association between gender and pressure pain threshold in the unaffected leg as 
males could tolerate higher pressure than females (P=0.05). No other associations between 
gender and pain sensitivity were found (All P>0.05) 
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Genetic associations with demographic characteristics  
Non-carriers of the OPRM1 rs589046T, OPRM1 rs563649T or OPRK1 rs1365098T alleles 
were taller than carriers (172.2 cm vs. 168.3 cm; P=0.04; 171.3 cm vs. 163.3 cm; P=0.01 and 
172.2 cm vs. 168.3 cm; P=0.04) (Table 1). In addition, non-carriers of the OPRM1 
rs9479757A allele weighed more than carriers (84 kg vs. 70 kg; P=0.04). No other SNPs 
were associated with height or weight (P>0.05). 
 
Genetic associations with pain sensitivity 
Clinical pain rating during hip rotation 
A higher rating of pain intensity (15.6%) was seen in carriers of the OPRM1 rs589046T allele 
(mean of 5.9 (4.5 to 7.4); n=38) compared with non-carriers (mean of 5.1 (4.5 to 5.7); n=47; 
effect size: 0.8; P=0.04) (figure 3, Table 3), indicating a higher sensitivity to pain in the 
patients with the T allele. No other SNPs were associated with clinical pain ratings (P>0.05) 
 Additionally, an explorative analysis showed that a higher rating of pain intensity was seen 
in patients in opioid treatment compared with patients in no opioid treatment (P=0.02).  
 
Heat PDTs 
A genetic association was seen between the OPRD1 SNP rs2234918 and PDT to contact heat 
stimulation (P=0.001) (figure 2, Table 3). A higher PDT (5.1%) was seen in carriers of the 
rs2234918C allele (mean of 47.5C (46.9 to 48.1C); n=60) compared with non-carriers 
(mean of 45.2C (43.7 to 46.7C); n=29; effect size: 2.3C) (figure 4), indicating lower 
sensitivity to pain in the patients with the C allele. No other SNPs were associated with 
contact heat PDT (P>0.05) 
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CPM effect 
The most distinct CPM effect was seen 120 seconds after initiation of the cold pressor test. 
Thus, values at this time point was used for further analysis. A more evident  CPM effect 
(94.7%) was seen in carriers of the OPRM1 rs589046T allele (pre-CPM heat PDT of 46.4C; 
peri-CPM heat PDT of 47.1C; CPM  mean of 3.7% (2.5 to 5.0%); n=41) compared with 
non-carriers (pre-CPM heat PDT of 47.9C; peri-CPM heat PDT of 48.0C mean of 1.9% 
(0.8 to 3.2%); n=44; effect size: 1.8; P=0.05) (figure 5, Table 3), indicating a more 
pronounced pain modulation in patients with the T allele.  
 
Pressure pain threshold  
No SNPs were associated with pressure pain threshold at tibia in either the affected or 
unaffected hip (P>0.05) (Table 3). 
 
DISCUSSION 
The presented results support the hypothesis that carriage of the minor allele of ORPM1 
(rs589046) or OPRD1 (rs2234918) was associated with pain sensitivity in patients with 
osteoarthritis of the hip.  
 
Interactions with demographics 
Males tolerated higher pressure in the unaffected leg than females. This confirms  results 
from a previous study,  the results of which showed that males could tolerate higher muscle 
pressure than females 
16
. Additionally, sensitivity to pressure has been postulated to be 
genetically associated with an OPRM1 rs1799971 SNP, however, only in males 
26
. Recently, 
height has been suggested to be a classical polygenetic trait associated with newly discovered 
genetic factors 
27
.  Additionally, some investigators have suggested that gender differences in 
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body height may be associated with differences in pain sensitivity based on the belief that the 
body height would be inversely related to the density of peripheral nociceptors 
28
. For 
example, results from a previous study has shown that height was negatively associated with 
cold pressor-induced pain thresholds in females 
4
. In the present study, we found a difference 
in height between the carriers and non-carriers group for the OPRM1 rs589046, OPRM1 
rs563649 and OPRK1 rs1365098 SNPs. Thus, for further investigation of inter-individual 
variability in pain sensitivity, height might be included as a co-factor in the analysis. 
 
Association between genetic factors and pain 
No associations were found between COMT and pain sensitivity. However,  results from 
other studies have demonstrated association between COMT and pain phenotypes 
7,14,29
. Only 
one polymorphism of the COMT gene was investigated in the present study and this may 
explain the discrepancy, as it has been demonstrated that COMT contains at least five 
functional polymorphisms that impact its biological activity and associated phenotypes
29
. 
Thus, it cannot be excluded that other COMT polymorphisms are associated with pain 
phenotype in OA.  
 
Carriage of the widely studied OPRM1 rs1799971G allele has been found to be associated 
with higher thresholds to pressure pain, which indicates a lower pain sensitivity to pressure in 
participants carrying the G allele 
26
. However, despite several reports of positive associations 
between the rs1799971 SNP of OPRM1 and altered pain sensitivity,  based on the results of a 
meta-analysis of published genetic association studies it was concluded that the rs1799971 
SNP is inconsistently associated with altered pain-related phenotypes 
30
. The results from the 
present study and from another study in patients with knee OA 
6
 also failed to confirm 
association between this specific allele and pain sensitivity. However, in the present study, 
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other OPRM1 SNPs were explored and it was found that the OPRM1 rs589046T allele was 
associated with increased perceived pain intensity during hip rotation and also with a more 
pronounced CPM effect. These findings are contradictory as a high pain rating is normally 
associated with a poor pain modulation (reduced CPM effect). In summary, the well-studied 
OPRM1 rs1799971 SNP could not be associated with pain sensitivity in the OA patient 
population. However, less-studied OPRM1 SNPs were found to be associated with pain 
sensitivity and therefore, for future studies we recommend including several SNPs of the 
same gene. 
In healthy volunteers, it has been demonstrated that carriers of OPRK1 rs6473799C allele had 
higher pain tolerance threshold to mechanical visceral stimulation 
31
. Additionally, it has been 
demonstrated that two other OPRK1 SNPs (rs7016778 and rs7824175) are associated with 
the pain tolerance threshold to muscle pressure stimulation 
16
. However, in the present study 
no associations to OPRK1 SNPs were found. This may be explained by the use of other pain 
models as specific experimental-pain paradigms are controlled by partially distinct 
nociceptive mechanisms based on the pain-evoking stimuli. It has been suggested that these 
distinct mechanisms may be influenced by different sets of genes 
32
.     
Results from experimental pain studies in healthy volunteers have shown no differences in 
pain thresholds to contact heat stimulations between carriers and non-carriers of different 
OPRD1 SNPs 
16,31,33,34
. However, in this study in patients with OA, the carriers of OPRD1 
rs2234918C allele reported higher PDT to contact heat stimulation compared with non-
carriers, indicating a lower pain sensitivity in patients with the C allele. OPRD1 is thought to 
be involved in neuropathic and inflammatory pain perception 
35,36
, hence, investigating the 
influence of  OPRD1 SNPs on these pain types in clinical studies is recommended. 
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Gene selection 
The investigated candidate  genes were selected based on previous work
16,25,31,37
, although 
they are not specific for pain, they may have an impact on the pain sensitivity as endogenous 
opioid-like ligands, enkephalins, interact with opioid receptors, and thereby may modulate 
the pain system 
38
. Catechol-O-methyltransferase has an indirect effect on the mu opioid 
receptor by changing its activity through enkephalin’s 
39
. In the present study, associations 
between altered pain sensitivity and variants of the opioid receptor genes (but not for COMT 
variants) were identified. It has been shown that other SNPs than the seventeen in the four 
candidate genes included in this study are associated with pain sensitivity. For example, cold 
pressor-induced pain sensitivity and osteoarthritis pain have previously shown to be 
associated with a SNP in the P2RX7 receptor gene 
3,11
. Additionally, if epistasis, which is the 
interaction between genes, is present, the effect of one SNP may be altered or masked by the 
effect of another SNP and thereby, reduce the power to detect genetic associations. Thus, it is 
difficult to exclude that other non-significant SNPs are associated with the assessment of pain 
sensitivity. Thus, in future studies with higher sample size epistatic effects should be 
considered. The sample size of this study was relatively small for a genetic association study, 
but the use of experimental measurements has the potential to minimize factors that may 
affect detection of true associations 
18
. Finally, each SNP was analyzed separately for each 
investigated assessment of pain sensitivity and therefore, the potential for an additive effect in 
patients with multiple genetic associations may exist. However, the present study was not 
designed and powered for a multipoint SNP analysis, as the aim was to investigate separate 
candidate polymorphisms. As increased sensitivity to noxious stimuli has been postulated as 
a risk factor for the development of chronic pain conditions 
14,40
,  following surgery it may be 
important to investigate if genetic polymorphisms can be used to predict the patients at high 
risk.  
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External validity 
We showed that using experimentally induced pain stimuli in patients suffering from clinical 
pain offers a new platform to explore the inter-individual difference in pain sensitivity to the 
actual pain states of interest, relatively free of confounders seen in traditional clinical studies. 
The investigation of genetic association with variability in pain sensitivity may be of 
particular relevance for patients with inflammatory pain disorders, such as osteoarthritis, as 
these disorders are characterized by an increased pain sensitivity 
20
.  
 
CONCLUSION 
Results from the present study suggest that, in patients with hip osteoarthritis, genetic 
variants in OPRM1 and OPRD1 may contribute to the variability in pain sensitivity. Clinical 
relevance cannot be confirmed from the present study as many other factors as e.g. 
psychological status may also play a role in individual sensitivity to noxious stimuli. 
However, the results adds information on opioid receptor polymorphisms and indicates that 
other polymorphisms than the most studied OPRM1 rs1799971 may play an important role.  
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TABLES  
Table 1. Genotype distribution and corresponding demographic characteristics of the study population (n=92) 
 
Gene dbSNP Genotype N D 
Gender 
(female:male) 
Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m
2
) 
Duration of hip pain 
(years) 
-opioid 
receptor 
(OPRM) 
rs1799971 AA 73 0.80 39:34 
 
11:8 
66 (58-74) 
 
66 (60-73) 
170 (164-176) 
 
172 (165-175) 
83 (68-90) 
 
78 (68-88) 
27 (25-31) 
 
26 (24-31) 
4 (3-5) 
AG 17 0.18 
5 (4-6) 
GG 2 0.02 
 rs589046 CC 47 0.51 24:24 66 (56-74) 172 (167-177) 83 (68-94) 27 (24-31) 4 (3-5) 
  CT 35 0.38 
26:18 68 (58-74) 168 (161-176) 82 (69-87) 27 (25-31) 4.5 (3-5.5) 
  TT 10 0.11 
 rs563649 CC 81 0.88 42:39 66 (56-74) 172 (165-177) 83 (69-90) 27 (24-30) 4 (3-5) 
  CT 10 0.11 
8:3 66 (60-73) 163 (160-168) 72 (65-93) 28 (25-32) 5 (4-6) 
  TT 1 0.01 
 rs9479757 GG 71 0.77 36:35 66 (58-74) 171 (166-177) 84 (70-90) 27 (25-31) 4 (3-5) 
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  AG 18 0.20 
14:7 66 (58-73) 165 (162-175) 70 (64-85) 26 (24-28) 5 (4-5) 
  AA 3 0.03 
 rs533586 TT 33 0.36 17:16 64 (58-72) 172 (164-177) 83 (71-88) 27 (25-32 5 (4-6) 
  TC 45 0.49 
33:26 67 (58-74) 170 (164-176) 83 (66-90) 27 (25-30) 4 (3-5) 
  CC 14 0.15 
-opioid 
receptor 
(OPRK) 
rs16918875 CC 88 0.96 47:41 
 
3:1 
67 (58-74) 
 
58 (54-66) 
171 (164-176) 
 
168 (166-173) 
83 (67-90) 
 
85 (76-94) 
27 (24-31) 
 
29 (28-32) 
4 (3-5) 
CT 4 0.04 
3 (2-5) 
TT 0 0 
 rs7016778 TT 76 0.83 42:34 66 (58-74) 172 (163-178) 84 (67-90) 27 (24-31) 4 (3-5) 
  TA 15 0.16 
8:8 67 (58-72) 169 (166-172) 79 (71-89) 28 (25-31) 5 (3.5-6) 
  AA 1 0.01 
 rs10504151 TT 84 0.91 45:39 67 (58-74) 171 (164-177) 82 (67-89) 27 (24-30) 4 (3-5) 
  TC 8 0.09 
5:3 59 (54-67) 168 (166-171) 87 (76-92) 29 (27-33) 4.5 (3-6) 
  CC 0 0 
 rs7836120 AA 73 0.79 40:33 66 (58-74) 172 (164-178) 84 (67-90) 27 (24-31) 4 (3-5) 
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  AG 17 0.19 
10:9 66 (54-72) 169 (166-172) 80 (71-90) 28 (26-31) 5 (4-6) 
  GG 2 0.02 
 rs6473799 TT 47 0.51 27:20 66 (58-74) 172 (165-176) 85 (69-90) 27 (24-31) 4 (3-5) 
  TC 36 0.39 
23:22 66 (58-73) 169 (162-176) 80 (67-88) 27 (25-31) 5 (4-6) 
  CC 9 0.10 
 rs1365098 GG 47 0.51 25:22 66 (58-74) 174 (165-179) 85 (69-90) 27 (24-31 4 (3-5) 
  GT 34 0.37 
25:20 67 (58-73) 168 (162-175) 80 (67-87) 27 (25-31 5 (4-6) 
  TT 11 0.12 
 rs7824175 GG 72 0.78 40:32 66 (58-74) 171 (165-176) 84 (70-90) 27 (25-31 4 (3-5.5) 
  GC 17 0.19 
10:10 71 (59-76) 170 (159-178) 76 (66-86) 27 (23-29) 4.5 (3-5) 
  CC 3 0.03 
 rs963549 GG 68 0.74 37:31 66 (58-74) 171 (165-176) 84 (69-90) 27 (25-31 4 (3-5.5) 
  GA 21 0.23 
13:11 68 (56-74) 169 (161-177) 81 (67-87) 27 (24-29) 4.5 (3.5) 
  AA 3 0.03 
-opioid rs533123 AA 54 0.59 28:26 69 (59-74) 172 (165-176) 84 (70-90) 28 (26-31) 4 (3-6) 
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receptor 
(OPRD) 
AG 34 0.37  
22:16 
 
64 (54-74) 
 
170 (163-177) 
 
80 (64-90) 
 
26 (24-31) 
5 (3-5) 
GG 4 0.04 
 rs2236857 TT 55 0.60 31:24 65 (56-73) 170 (163-176) 80 (68-89) 26 (24-31) 5 (3-6) 
  TC 30 0.33 
19:18 69 (59-74) 172 (164-176) 85 (69-90) 27 (25-30) 4 (3-5) 
  CC 7 0.08 
 rs2234918 TT 29 0.32 17:12 68 (58-74) 168 (163-175) 83 (70-90) 27 (24-34) 4 (3-6) 
  TC 50 0.54 
33:30 66 (58-74) 171 (165-179) 83 (67-90) 27 (25-30) 4 (3-5) 
  CC 13 0.14 
COMT rs4680 AA 31 0.34 14:17 63 (54-73) 171 (164-178) 85 (67-94) 27 (25-33) 4 (3-6) 
  AG 45 0.49 
36:25 69 (58-74) 170 (164-176) 81 (69-88) 27 (24-30) 4 (3-5) 
  GG 16 0.17 
 
dbSNP = single nucleotide polymorphism database identification; D = distribution; demographic characteristics are for the carriers of the minor allele vs. for the non-carriers of the minor allele; age, height, weight and 
BMI are represented as median (25th -75th percentile); BMI = body mass index; Bold typing indicates that there is a significant difference between carriers of the minor allele and non-carriers of the minor allele. 
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Table 2. Measurements for pain sensitivity in males and females 
 
Parameters 
Males  Females 
N Median (25
th
-75
th
)  N Median (25
th
-75
th
) 
Measurements for pain sensitivity:      
Clinical pain rating during hip rotation (NRS) 41 5 (4-6)  44 6 (5-7) 
Heat PDTs (°C) 41 47.8 (45.9-49.1)  48 47.8 (45.5-48.7) 
CPM effect (%) 38 1.5 (0.6-4.7)  47 2.4 (0.7-5.2) 
Pressure pain thresholds in the affected hip (kPa) 42 71 (54.5-83.5)  50 64.8 (53.5-77.8) 
Pressure pain thresholds in the unaffected hip (kPa) 42 73.4 (60.8-90.8)  50 57.7 (47-69.8) 
  
N = number of patients; BMI = body mass index; NRS = numeric rating scale; PDTs = pain detection thresholds; 25th-75th percentiles; Bold 
parameter indicates that there is a significant difference between males and females 
 
Table 3. Summary of the genetic associations with the assessment of pain sensitivity   
* indicates that the specific SNP was associated with more than one assessment, - indicates that no significant association could be 
demonstrated. 
 
 
Assessment of pain sensitivity 
COMT OPRM1 OPRK1 OPRD1 
Clinical pain rating during hip rotation - rs589046* - - 
Heat pain detection threshold - - - rs2234918 
CPM effect - rs589046* - - 
Pressure pain threshold in the affected hip - - - - 
Pressure pain threshold in the unaffected hip - - - - 
Candidate genes 
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FIGURE LEGENDS 
Figure 1. Flow diagram of the procedures  
 
Figure 2. A flow diagram showing the process from patient screening to inclusion.  
 
Figure 3. Clinical pain rating during hip rotation and the OPRM1 rs589046T SNP (univariate analysis) 
A higher clinical pain rating was seen in carriers of the OPRM1 rs589046T allele (n=38) compared with non-
carriers (n=47; effect size: 0.8; P=0.04), NRS = numerical pain rating from zero to ten, horizontal line 
represents the mean 
 
Figure 4. Pain detection thresholds to contact heat stimulation and the OPRD1 rs2234918 SNP (univariate 
analysis) 
A higher heat PDT was seen in carriers of the OPRD1 rs2234918C allele (n=60) compared with non-carriers 
(n=29; effect size: 2.3 °C; P=0.001), PDTs = heat pain detection thresholds 
 
Figure 5. CPM effect and the OPRM1 rs589046 SNP (univariate analysis) 
A higher CPM effect was seen in carriers of the OPRM1 rs589046T allele (n=41) compared with non-carriers 
(n=44; effect size: 1.8; P=0.05) 
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Figure 2. 
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Figure 4. 
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Figure 5. 
 
 
 
